Deals
Actavis Said to Near $25 Billion Deal to Buy Forest Labs
This article is for subscribers only.
Actavis Plc, the world’s second-largest generic-drug maker by market value, is close to an agreement to buy Forest Laboratories Inc. for about $25 billion, said a person familiar with the matter.
The acquisition may be announced as early as today U.S. time, said the person, who asked not to be identified as the talks are private. New York-based Forest had a market value of $19.3 billion when trading closed Feb. 14. The Wall Street Journal reported on the deal earlier. The deal would be a win for billionaire investor Carl Icahn, who gained a board seat at Forest in 2012 and is the second-largest shareholder.